Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SLC18A3 | Q16572 | 6/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24700142 | 0.88 | NAMPT (0.45) | NAMPTKDM4ESLC18A3HCRTR2GPR119 | |
| SCHEMBL24700413 | 0.87 | AGTR2 (0.43) | ALDH1A1HCRTR2 | |
| Formamide SCHEMBL8801927 | 0.83 | NAMPT (0.41) | NAMPTKDM4ESLC18A3HCRTR2GPR119 | |
| SCHEMBL29795102 | 0.81 | SLC18A3 (0.42) | KDM4EALDH1A1SLC18A3OPRL1 | |
| SCHEMBL24700468 | 0.81 | RIPK1 (0.41) | KDM4EGPR119PKM | |
| SCHEMBL24700163 | 0.80 | HPGD (0.43) | ALDH1A1 | |
| SCHEMBL4077656 | 0.79 | NAMPT (0.54) | NAMPTGRIN2BKDM4EALDH1A1TACR1 | |
| SCHEMBL16004560 | 0.78 | RORC (0.46) | NAMPTTACR1GPR119 | |
| SCHEMBL24700587 | 0.78 | CHRM2 (0.36) | — | |
| SCHEMBL30761098 | 0.77 | USP2 (0.47) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220380314-A1 | SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2022-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380314-A1 | SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GBA2, CLN6 | NAMPT 92/4885GRIN2B 1116/4885KDM4E 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.